Durable treatment of ameloblastoma with single agent BRAFi Re: Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma

Recurrence rate following treatment for primary multicystic ameloblastoma: systematic review and meta-analysis

(2016) R. de A.C. Almeida et al.   INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activating FGFR2-RAS-BRAF Mutations in Ameloblastoma

(2014) N. A. Brown et al.   CLINICAL CANCER RESEARCH

Clinical and Radiographic Response With Combined BRAF-Targeted Therapy in Stage 4 Ameloblastoma

(2014) F. J. Kaye et al.   JNCI-Journal of the National Cancer Institute

Identification of recurrent SMO and BRAF mutations in ameloblastomas

(2014) Robert T Sweeney et al.   NATURE GENETICS

High frequency of BRAFV600E mutations in ameloblastoma

(2013) Kari J Kurppa et al.   JOURNAL OF PATHOLOGY

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE